Screener
CRISPR Therapeutics CRSP Total Revenue
Total Revenue at other companies
Segments
By product
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Revenue: | ||
| Collaboration revenue | $1,000 | — |
| Grant revenue | 458 | 865 |
| Total revenue | 1,458 | 865 |
| Operating expenses: | ||
| Research and development | 68,574 | 72,484 |
| General and administrative | 17,183 | 19,296 |
| Collaboration expense, net | 45,949 | 57,509 |
Item 1. Financial Statements
FAQ
- What is CRISPR Therapeutics's total revenue?
- CRISPR Therapeutics (CRSP) reported total revenue of $1.46M in Q1 2026.
- How has CRISPR Therapeutics's total revenue changed year-over-year?
- CRISPR Therapeutics's total revenue increased by 68.6% year-over-year, from $865K to $1.46M.
- What is the long-term trend for CRISPR Therapeutics's total revenue?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's total revenue has grown at a -75.1% compound annual growth rate (CAGR), from $914.96M to $3.51M.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about CRISPR Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude